Updated:
Applied DNA Sciences
Applied DNA Sciences operates out of Stony Brook, New York, where it designs and produces DNA via polymerase chain reaction (PCR) and enzymatic synthesis.
Applied DNA Sciences
Applied DNA Sciences operates out of Stony Brook, New York, where it designs and produces DNA via polymerase chain reaction (PCR) and enzymatic synthesis. The company does not function as a family office or an asset manager. It is a publicly traded entity—Nasdaq listed—that sells DNA as an input for genetic-medicine manufacturers. Its core commercial product, lineaDNA™, is offered as a template for mRNA production and for gene- and cell-therapy applications. The firm’s commercial focus is the therapeutic-DNA supply chain. It manufactures linear DNA, which downstream customers use to produce messenger RNA vaccines and advanced therapies. Unlike many biotech peers that pursue drug candidates of their own, Applied DNA Sciences supplies the platform ingredient. The company markets to pharmaceutical developers and CDMOs, making its revenue model that of a specialized ingredient manufacturer rather than a clinical-stage biopharma. No specific customer names or volume commitments appear in the public materials reviewed. Public disclosures did not provide a team headcount, a deployment figure, or a named management roster beyond the investor-relations contact. The firm maintains a single location on Long Island and lists no additional laboratories or offices. Investor communications are managed through an external firm, ICR, suggesting a lean internal administrative footprint. No philanthropic foundation, adjacent investment vehicle, or co-investment club was disclosed. What sets Applied DNA Sciences apart structurally is its role as a pure-play DNA inputs company. It does not develop its own drug pipeline, instead supplying the enabling chemistry to the therapeutics industry. That makes its economics tied to tool-and-ingredient demand cycles rather than binary drug-approval outcomes—a model that looks more like a specialty-chemicals business than a traditional biotech.
General information
Firm type
Biotechnology Company
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Stony Brook
Corporate office
Stony Brook, NY, United States
Sector focus
Frequently asked questions
What does Applied DNA Sciences actually sell?
Its primary commercial offering is lineaDNA™, a linear form of DNA manufactured via polymerase chain reaction (PCR) and enzymatic synthesis. The company ships this as a raw material to pharmaceutical firms and CDMOs that use it to produce messenger RNA, gene-therapy vectors, and cell-therapy constructs. Revenue comes from the sale of these DNA inputs, not from developing drugs internally.
Does the company run its own drug pipeline?
No. Applied DNA Sciences is structured as a supplier of manufacturing inputs. Public materials emphasize its role in enabling other companies’ mRNA and gene-therapy programs rather than pursuing clinical trials or drug approvals of its own.
Is Applied DNA Sciences a family office or an investment vehicle?
No. It is a publicly traded biotechnology company listed on Nasdaq. There is no publicly available information linking it to family-office activity, wealth management, or external investment management.
What kind of DNA does the company produce, and why does the shape matter?
The firm produces linear DNA—a double-stranded, non-circular form—as opposed to the plasmid DNA that has historically dominated therapeutic manufacturing. The linear format is designed to eliminate the backbone sequences that plasmids carry, which the company argues can improve safety and simplify downstream processing in mRNA and gene-therapy production.
Where is the company's physical production located?
Publicly available materials indicate a single headquarters and operational site in Stony Brook, New York. No additional laboratories, manufacturing sites, or international offices were disclosed in the sources consulted.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: